Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where K. Ijichi is active.

Publication


Featured researches published by K. Ijichi.


Archives of Virology | 1998

Upregulation of HIV-1 replication in chronically infected cells by ingenol derivatives

Masatoshi Fujiwara; Mika Okamoto; K. Ijichi; Kenji Tokuhisa; Yasuaki Hanasaki; Kimio Katsuura; Daisuke Uemura; Shiro Shigeta; Kenji Konno; Tomoyuki Yokota; Masanori Baba

SummaryWe have previously reported that ingenol derivatives are highly potent inhibitors of human immunodeficiency virus type 1 (HIV-1) replication in acutely infected cells. In this study, however, we have found that some ingenol derivatives strongly enhance the replication of HIV-1 in chronically infected cells at nanomolar concentrations. One of the derivatives could activate nuclear factor κB(NF-κB), a potent inducer of HIV-1 replication, through the activation of protein kinase C (PKC). Whereas another derivative, which affected neither PKC nor NF-κB, significantly enhanced HIV-1 replication, suggesting that a PKC-independent mechanism may also exist in ingenol derivative-induced HIV-1 upregulation.


Antiviral Research | 1996

Anti-HIV-1 activity of thiadiazole derivatives : structure-activity relationship, reverse transcriptase inhibition, and lipophilicity

K. Ijichi; Masatoshi Fujiwara; Hideki Nagano; Yukiharu Matsumoto; Yasuaki Hanasaki; Teruhiko Ide; Kimio Katsuura; Hiromitsu Takayama; Seiichiro Shirakawa; Norio Aimi; Shiro Shigeta; Kenji Konno; Masaaki Matsushima; Tomoyuki Yokota; Masanori Baba

The structure-activity relationship of the non-nucleoside HIV-1-specific reverse transcriptase (RT) inhibitors 4-phenyl-1,2,5-thiadiazol-3-yl N,N-dialkylcarbamate (TDA) derivatives was investigated with respect to their anti-HIV-1 activity, RT inhibition, and lipophilicity. 4-Phenyl-1,2,5-thiadiazol-3-yl N,N-dimethylcarbamate inhibited HIV-1-induced cytopathic effect (CPE) by 50% at a concentration of 28.8 microM in MT-4 cells. The activity increased more than 100-fold when the hydrogens at the 2-position and the 6-position in phenyl moiety were substituted by chlorines. However, the derivative with a chlorine at the 4-position of phenyl moiety did not show any inhibition of HIV-1 replication at its non-toxic concentrations. All of the 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-yl N-methyl-N-alkylcarbamates proved inhibitory to HIV-1 replication in the nanomolar concentration range. The TDA derivatives that showed anti-HIV-1 activity also inhibited RT activity in an enzymatic assay. However, the TDA derivatives did not show any specific inhibition of a non-nucleoside RT inhibitor (NNRTI)-resistant mutant and its RT activity. When the TDA derivatives were examined for their inhibitory effect on HIV-1 replication in the presence of 50% human serum, the activity significantly decreased depending on-their lipophilicity.


Bioorganic & Medicinal Chemistry Letters | 1996

Utilization of wieland furoxan synthesis for preparation of 4-aryl-1,2,5-oxadiazole-3-yl carbamate derivatives having potent anti-HIV activity

Hiromitsu Takayama; Seiichiro Shirakawa; Mariko Kitajima; Norio Aimi; Kentaro Yamaguchi; Yasuaki Hanasaki; Teruhiko Ide; Kimio Katsuura; Masatoshi Fujiwara; K. Ijichi; Kenji Konno; Shiro Sigeta; Tomoyuki Yokota; Masanori Baba

Abstract The classical Wieland furoxan synthesis was reinvestigated and this procedure was applied to the preparation of 4-aryl-1,2,5-oxadiazole-3-yl N,N-dialkylcarbamate derivatives, which were found to exhibit potent anti-HIV-1 activity.


Antimicrobial Agents and Chemotherapy | 1996

Mechanism of selective inhibition of human immunodeficiency virus by ingenol triacetate.

Masatoshi Fujiwara; K. Ijichi; Kenji Tokuhisa; Kimio Katsuura; Shiro Shigeta; Kenji Konno; Gui-Yang-Sheng Wang; Daisuke Uemura; Tomoyuki Yokota; Masanori Baba


Journal of Medicinal Chemistry | 1995

Thiadiazole derivatives : highly potent and specific HIV-1 reverse transcriptase inhibitors

Yasuaki Hanasaki; Hiroshi Watanabe; Kimio Katsuura; Hiromitsu Takayama; Seiichiro Shirakawa; Kentaro Yamaguchi; Shin-ichiro Sakai; K. Ijichi; Masatoshi Fujiwara; Kenji Konno


Antimicrobial Agents and Chemotherapy | 1995

Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-Y1 N,N-dialkylcarbamate derivatives.

K. Ijichi; Masatoshi Fujiwara; Y Hanasaki; H Watanabe; Kimio Katsuura; H Takayama; S Shirakawa; S Sakai; Shiro Shigeta; Kenji Konno


Antiviral Research | 1995

Thiadiazole derivatives as highly potent inhibitor of human immunodeficiency virus type 1 (HIV-1)

Masatoshi Fujiwara; K. Ijichi; Kenji Konno; Tomoyuki Yokota; Yasuaki Hanasaki; H. Watanabe; Kimio Katsuura; Seiichiro Shirakawa; Hiromitsu Takayama; S. Sakai; Shiro Shigeta; Masanori Baba


Antiviral Research | 1995

Ingenol derivatives, ingredient of ‘Kansui’, are highly potent inhibitor of HIV

Masatoshi Fujiwara; K. Ijichi; Kenji Konno; Tomoyuki Yokota; K. Tokuhisa; Kimio Katsuura; D. Uemura; Shiro Shigeta; Masanori Baba


Antiviral Research | 1996

Structure - activity relationship of non-nucleoside RT inhibitor, thiadizaole derivatives

H. Nagano; K. Ijichi; Masatoshi Fujiwara; Yukiharu Matsumoto; Kenji Konno; Tomoyuki Yokota; M. Matsushima; Yasuaki Hanasaki; Kimio Katsuura; Hiromitsu Takayama; Norio Aimi; Masanori Baba; Shiro Shigeta


Antiviral Research | 1995

3-dimensional structure studies of thiadiazole-derivatives for anti-HIV-1 RT activity

H. Nagano; K. Ijichi; Yukiharu Matsumoto; Masatoshi Fujiwara; Yasuaki Hanasaki; H. Watanabe; M. Katsuura; Seiichiro Shirakawa; Hiromitsu Takayama; S. Sakai; Shiro Shigeta; Kenji Konno; Masanori Baba; M. Matsushima; Tomoyuki Yokota

Collaboration


Dive into the K. Ijichi's collaboration.

Top Co-Authors

Avatar

Kenji Konno

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Masatoshi Fujiwara

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Shiro Shigeta

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge